BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4

BioNTech’s Focus on Oncology and Innovative Therapies

Headquartered in Mainz, Germany, BioNTech SE is a global biopharmaceutical company dedicated to developing pioneering therapies for cancer and other serious diseases. Oncology remains a central pillar of its strategy, aiming to revolutionize cancer treatment through innovative approaches spanning early to late-stage disease. This comprehensive focus positions BioNTech as a leader in immuno-oncology and personalized medicine.

The company’s expanding late-stage oncology pipeline includes diverse treatment modalities such as immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. These complementary approaches target cancer through multiple mechanisms, potentially offering synergistic benefits. BioNTech’s goal is to broaden treatment options across various cancer types and patient groups, addressing significant unmet medical needs.

Strategic Collaborations Driving Pipeline Advancement

BioNTech has formed multiple strategic partnerships with global pharmaceutical leaders and specialized biotech firms to accelerate innovation and clinical progress. Recognizing the value of collaboration, these alliances enhance the speed and success of bringing transformative therapies to patients. Partners include Bristol Myers Squibb, Duality Biologics, Genentech (Roche Group), Genmab, MediLink, OncoC4, and Pfizer.

These collaborations span various therapeutic areas and modalities, providing BioNTech with access to scientific expertise, manufacturing capabilities, and commercial resources. Such partnerships are critical in oncology development due to the complexity of drug design, regulatory approval, and global commercialization.

Upcoming Financial Results and Investor Engagement

On August 4, 2026, BioNTech will disclose its Q2 2026 financial results, offering investors key operational and financial insights for the period. This update will enable analysts and institutional investors to evaluate the company’s progress and adjust forecasts for the remainder of the fiscal year.

Simultaneously, BioNTech will host a live conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss results, strategic initiatives, and future outlook. This forum facilitates direct interaction with investors, analysts, and the public, ensuring broad accessibility across time zones and communication preferences.

How to Access the Conference Call and Webcast

Investors and analysts can register in advance for telephone participation via a dedicated registration link, which provides dial-in numbers and a unique PIN. Early registration is recommended to avoid technical delays.

For webcast access, BioNTech will stream the live presentation alongside downloadable slides through multiple channels, including a public webcast link and the "Events & Presentations" section on the Investor Relations page at www.BioNTech.com. This ensures flexible access options for all stakeholders.

Webcast Replay Availability

Following the live event, a replay of the webcast will be archived on BioNTech’s website for 30 days, allowing those unable to attend live to review the presentation and discussion at their convenience. This extended availability supports international investors, analysts, and retail participants in analyzing the company’s performance.

The archived webcast enables ongoing reference and comparison of quarterly progress and management commentary consistency.

BioNTech’s Global Presence and Headquarters

Based in Mainz, Germany, BioNTech operates globally with strategic operations across multiple international markets and regulatory environments. Its location in Mainz situates it within Germany’s biotechnology hub, close to leading research institutions and regulatory authorities.

Listed on Nasdaq under ticker BNTX (and 0A3M in select UK markets), BioNTech maintains significant exposure to North American markets while leveraging European research and regulatory expertise. Its global footprint is further extended through partnerships with international pharmaceutical companies.

Investor Relations and Media Contacts

BioNTech provides dedicated contacts for investor and media inquiries. Douglas Maffei, PhD, handles investor relations and can be reached at [email protected]. Jasmina Alatovic manages media relations and is available at [email protected]. These contacts ensure transparent communication with financial stakeholders and the media.

Additional company information, including pipeline details and corporate updates, is accessible at www.BioNTech.com.

Competitive Edge in Next-Generation Immuno-Oncology

BioNTech’s focus on mRNA immunotherapies, antibody drug conjugates, and immunomodulators aligns with industry trends toward personalized and mechanism-driven cancer treatments. Its diversified late-stage oncology pipeline and strategic partnerships with major pharmaceutical firms enhance its competitive positioning and ability to advance transformative therapies.

The upcoming Q2 2026 results will offer insights into BioNTech’s clinical progress and success in progressing candidates through late-stage development.

Risks in Biopharmaceutical Oncology Development

Operating at the forefront of innovative cancer therapies, BioNTech faces inherent risks including regulatory challenges, clinical trial uncertainties, and competitive pressures. Development setbacks, evolving treatment standards, and reimbursement changes may impact commercial success. The Q2 2026 results will provide investors with management’s assessment of these risks and opportunities.